Study of FTY720 in Patients With Uveitis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE2

Study Classification

INTERVENTIONAL

Study Start Date

2013-11-30

Study Completion Date

2014-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will assess the safety, tolerability, and efficacy of FTY720 in patients with acute, noninfectious intermediate, posterior and pan uveitis

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety &Efficacy of CF101 to Subjects With Uveitis

NCT01905124

Uveitis, Posterior Uveitis, Intermediate

WITHDRAWN PHASE2

Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal Insert

NCT01694186

Non-Infectious Uveitis

COMPLETED PHASE3

Safety and Efficacy of Fluocinolone Acetonide Intravitreal Implants

NCT00407082

Noninfectious Posterior Uveitis

COMPLETED PHASE2/PHASE3

Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal (FAI) Insert

NCT05070728

Uveitis Uveitis, Posterior Uveitis, Intermediate

TERMINATED PHASE3

Study of Difluprednate Ophthalmic Emulsion in the Treatment of Uveitis

NCT00405496

Anterior Uveitis

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Noninfectious Posterior, Intermediate, or Pan Uveitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

FTY720

Fingolimod

Group Type EXPERIMENTAL

FTY720

Intervention Type DRUG

Fingolimod

Oral Corticosteroid

Group Type ACTIVE_COMPARATOR

Oral Corticosteroid

Intervention Type DRUG

Oral Corticosteroid

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

FTY720

Fingolimod

Intervention Type DRUG

Oral Corticosteroid

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Acute noninfectious posterior, intermediate, or pan uveitis
* Vitreous haze score of 1+ or more in the study eye at screening and baseline visits

Exclusion Criteria

* Vaso-occlusive vasculitis involving the retinal macula
* Behçet's uveitis
* Patients requiring corticosteroid or another systemic immunosuppressive medication for any other disease (e.g., asthma or some other autoimmune disease) that would contraindicate tapering (topical steroids permitted)
* Other protocol defined inclusions and/or exclusions may apply.

Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No